+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anxiolytics Market by Drug Class, Route Of Administration, Form, Distribution Channel, End User - Global Forecast to 2030- Product Image
Anxiolytics Market by Drug Class, Route Of Administration, Form, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Anxiolytics Market by Drug Class, Route Of Administration, Form, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887787
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anxiolytics market is undergoing rapid transformation as new drug classes and digital health technologies converge, shifting how anxiety disorders are managed globally. Senior leaders in the pharmaceutical sector are navigating changing regulations, evolving patient needs, and new trade dynamics, prompting a strategic reassessment of product portfolios and supply chains.

Market Snapshot: Anxiolytics Market Growth and Outlook

The anxiolytics market grew from USD 1.32 billion in 2024 to USD 1.42 billion in 2025. It is expected to continue growing at a CAGR of 7.37%, reaching USD 2.03 billion by 2030. Expansion is primarily driven by rising prevalence of anxiety disorders, technological advances in neuropharmacology, and shifting healthcare delivery models. With new regulatory measures accelerating innovative drug approvals and digital health channels improving patient engagement, this sector is poised for continued evolution. As the market diversifies, strategic planning by decision-makers will be crucial for sustained competitive advantage.

Scope & Segmentation

  • Drug Class: Azapirones (notably buspirone), Benzodiazepines (intermediate, long, and short acting types), Selective Serotonin Reuptake Inhibitors (escitalopram, paroxetine, sertraline), Serotonin Norepinephrine Reuptake Inhibitors (duloxetine, venlafaxine)
  • Route of Administration: Intranasal, oral, and parenteral (intramuscular, intravenous, subcutaneous) applications
  • Form: Capsule (hard gelatin, soft gelatin), injection, oral suspension, tablets (controlled release, immediate release)
  • Distribution Channel: Hospital pharmacies, online pharmacies, and retail pharmacies
  • End User: Clinics, homecare settings, and hospitals
  • Regional Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (spanning United Kingdom, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, other key markets), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Southeast Asian markets, others)
  • Leading Companies Analyzed: Pfizer Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Teva Pharmaceutical Industries Ltd, Viatris Inc., Sandoz International GmbH, Lundbeck A/S, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A.

Key Takeaways for Senior Decision-Makers

  • Product innovation is rapidly expanding, with newer drug classes and delivery systems increasingly tailored to reduce dependency risk and enhance patient adherence.
  • Digital therapeutics, telemedicine, and wearable technologies are being integrated alongside traditional treatments, expanding both access and engagement opportunities.
  • Regulatory agencies are streamlining drug approvals and emphasizing real-world evidence, requiring manufacturers to adapt lifecycle and market entry strategies accordingly.
  • Market competition now includes both branded innovators and generic manufacturers, intensifying the need for differentiation, cost management, and agile supply strategies.
  • Geographic growth patterns vary widely, with robust demand in North America, fast-developing markets in Asia-Pacific, and emerging opportunities in Latin America and Africa, each influenced by local payer and regulatory structures.

Tariff Impact on the Anxiolytics Market

Recent United States tariff adjustments have increased production costs for anxiolytic manufacturers, particularly those dependent on key active pharmaceutical ingredients from global suppliers. In response, companies are realigning sourcing strategies—shifting to domestic manufacturing or fostering new supplier partnerships—and re-evaluating cost structures. Downstream, these changes affect pharmacy pricing, reimbursement negotiations, and overall supply reliability, especially for commonly prescribed therapies. Market participants must stay alert to ongoing trade policy changes and actively diversify supply networks to maintain competitiveness.

Methodology & Data Sources

This report utilizes a robust methodology, including comprehensive secondary research from regulatory filings, industry publications, and trade databases, combined with structured interviews of key industry stakeholders. Data triangulation and validation ensure the accuracy and relevance of market insights presented to leadership teams.

Why This Report Matters

  • Enables C-suite leaders and strategy teams to benchmark emerging product classes, delivery innovations, and digital health integration in the anxiolytics space.
  • Provides actionable intelligence for supply chain risk mitigation, tariff navigation, and region-specific portfolio prioritization.
  • Supports informed decision-making on R&D investment, go-to-market strategies, and collaboration opportunities across major and evolving markets.

Conclusion

The anxiolytics market is evolving in complexity and opportunity. Strategic adaptability, focused innovation, and proactive supply management are essential for sustained growth and market leadership. This report equips senior decision-makers with the critical insights needed to define the next phase of success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anxiolytics Market, by Drug Class
8.1. Introduction
8.2. Azapirones
8.2.1. Buspirone
8.3. Benzodiazepines
8.3.1. Intermediate Acting
8.3.2. Long Acting
8.3.3. Short Acting
8.4. Selective Serotonin Reuptake Inhibitors
8.4.1. Escitalopram
8.4.2. Paroxetine
8.4.3. Sertraline
8.5. Serotonin Norepinephrine Reuptake Inhibitors
8.5.1. Duloxetine
8.5.2. Venlafaxine
9. Anxiolytics Market, by Route Of Administration
9.1. Introduction
9.2. Intranasal
9.3. Oral
9.4. Parenteral
9.4.1. Intramuscular
9.4.2. Intravenous
9.4.3. Subcutaneous
10. Anxiolytics Market, by Form
10.1. Introduction
10.2. Capsule
10.2.1. Hard Gelatin
10.2.2. Soft Gelatin
10.3. Injection
10.4. Oral Suspension
10.5. Tablet
10.5.1. Controlled Release
10.5.2. Immediate Release
11. Anxiolytics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Anxiolytics Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare Settings
12.4. Hospitals
13. Americas Anxiolytics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Anxiolytics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Anxiolytics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. F. Hoffmann-La Roche Ltd
16.3.3. Johnson & Johnson
16.3.4. Teva Pharmaceutical Industries Ltd
16.3.5. Viatris Inc.
16.3.6. Sandoz International GmbH
16.3.7. Lundbeck A/S
16.3.8. GlaxoSmithKline plc
16.3.9. Bristol-Myers Squibb Company
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANXIOLYTICS MARKET MULTI-CURRENCY
FIGURE 2. ANXIOLYTICS MARKET MULTI-LANGUAGE
FIGURE 3. ANXIOLYTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANXIOLYTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANXIOLYTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANXIOLYTICS MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANXIOLYTICS MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANXIOLYTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANXIOLYTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANXIOLYTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANXIOLYTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANXIOLYTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANXIOLYTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANXIOLYTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANXIOLYTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANXIOLYTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANXIOLYTICS MARKET SIZE, BY BUSPIRONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANXIOLYTICS MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANXIOLYTICS MARKET SIZE, BY SHORT ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANXIOLYTICS MARKET SIZE, BY ESCITALOPRAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANXIOLYTICS MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANXIOLYTICS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANXIOLYTICS MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANXIOLYTICS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANXIOLYTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANXIOLYTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANXIOLYTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANXIOLYTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANXIOLYTICS MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANXIOLYTICS MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANXIOLYTICS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANXIOLYTICS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANXIOLYTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANXIOLYTICS MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANXIOLYTICS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANXIOLYTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANXIOLYTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANXIOLYTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANXIOLYTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANXIOLYTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ANXIOLYTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ANXIOLYTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 77. CANADA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. CANADA ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 79. CANADA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 80. CANADA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. CANADA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. CANADA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. CANADA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 84. CANADA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 85. CANADA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 86. CANADA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 87. CANADA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. CANADA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. MEXICO ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 91. MEXICO ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 92. MEXICO ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. MEXICO ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. MEXICO ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 96. MEXICO ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 97. MEXICO ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 98. MEXICO ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 99. MEXICO ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. MEXICO ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. GERMANY ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. GERMANY ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 152. GERMANY ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 153. GERMANY ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. GERMANY ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 157. GERMANY ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 158. GERMANY ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 159. GERMANY ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 160. GERMANY ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. GERMANY ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. FRANCE ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. FRANCE ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 164. FRANCE ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 165. FRANCE ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 166. FRANCE ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 167. FRANCE ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. FRANCE ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 169. FRANCE ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 170. FRANCE ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 171. FRANCE ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 172. FRANCE ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. FRANCE ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. ITALY ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. ITALY ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 188. ITALY ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 189. ITALY ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. ITALY ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. ITALY ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. ITALY ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 193. ITALY ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 194. ITALY ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 195. ITALY ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 196. ITALY ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. ITALY ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. SPAIN ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. SPAIN ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 200. SPAIN ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 201. SPAIN ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. SPAIN ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 203. SPAIN ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SPAIN ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 205. SPAIN ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 206. SPAIN ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 207. SPAIN ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 208. SPAIN ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. SPAIN ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. DENMARK ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. DENMARK ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 248. DENMARK ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 249. DENMARK ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. DENMARK ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. DENMARK ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. DENMARK ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 253. DENMARK ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 254. DENMARK ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 255. DENMARK ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 256. DENMARK ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. DENMARK ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. QATAR ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. QATAR ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 272. QATAR ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 273. QATAR ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. QATAR ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 275. QATAR ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. QATAR ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 277. QATAR ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 278. QATAR ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 279. QATAR ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 280. QATAR ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. QATAR ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. FINLAND ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 283. FINLAND ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 284. FINLAND ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 285. FINLAND ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 286. FINLAND ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. FINLAND ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. FINLAND ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 289. FINLAND ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 290. FINLAND ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 291. FINLAND ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 292. FINLAND ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. FINLAND ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 304. SWEDEN ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. SWEDEN ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 313. NIGERIA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 314. NIGERIA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 315. NIGERIA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 316. NIGERIA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. NIGERIA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. EGYPT ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 319. EGYPT ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 320. EGYPT ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 321. EGYPT ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 322. EGYPT ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 323. EGYPT ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. EGYPT ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 325. EGYPT ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 326. EGYPT ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 327. EGYPT ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 328. EGYPT ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 329. EGYPT ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 330. TURKEY ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 331. TURKEY ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 332. TURKEY ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 333. TURKEY ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 334. TURKEY ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 335. TURKEY ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 336. TURKEY ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 337. TURKEY ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 338. TURKEY ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 339. TURKEY ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 340. TURKEY ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 341. TURKEY ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 342. ISRAEL ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 343. ISRAEL ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 344. ISRAEL ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 345. ISRAEL ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 346. ISRAEL ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 347. ISRAEL ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 348. ISRAEL ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 349. ISRAEL ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 350. ISRAEL ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 351. ISRAEL ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 352. ISRAEL ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 353. ISRAEL ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 354. NORWAY ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 355. NORWAY ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, 2018-2030 (USD MILLION)
TABLE 356. NORWAY ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 357. NORWAY ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 358. NORWAY ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 359. NORWAY ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 360. NORWAY ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MIL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Anxiolytics market report include:
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.
  • Sandoz International GmbH
  • Lundbeck A/S
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.42 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.03 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Anxiolytics - Global Strategic Business Report - Product Image

Anxiolytics - Global Strategic Business Report

  • Report
  • 108 Pages
  • Global
From
2025 Global Forecast for Anxiolytics Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Anxiolytics Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Generalized Anxiety Disorder - Pipeline Insight, 2025 - Product Image

Generalized Anxiety Disorder - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Hydroxyzine Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F - Product Image

Hydroxyzine Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F

  • Report
  • 188 Pages
  • Global
From
Anxiety Disorders and Depression Treatment Market Size, Share & Trends Analysis Report by Indication (Anxiety and Depression) by Drugs, Distribution Channel, Regional Outlook and Forecast, 2024-2031 - Product Image

Anxiety Disorders and Depression Treatment Market Size, Share & Trends Analysis Report by Indication (Anxiety and Depression) by Drugs, Distribution Channel, Regional Outlook and Forecast, 2024-2031

  • Report
  • 259 Pages
  • Global
From

About the Anxiolytic Market

Anxiolytic drugs, also known as anti-anxiety drugs, are a class of medications used to treat anxiety disorders. These drugs work by altering the levels of certain neurotransmitters in the brain, such as serotonin and dopamine, to reduce feelings of fear and anxiety. Commonly prescribed anxiolytics include benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), and tricyclic antidepressants. These drugs are used to treat a variety of anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder. Anxiolytics are widely prescribed and are generally considered safe and effective when used as directed. However, they can be habit-forming and may cause side effects such as drowsiness, dizziness, and confusion. As such, they should only be used under the supervision of a doctor. Some of the major companies in the anxiolytic market include Pfizer, GlaxoSmithKline, Eli Lilly, and AstraZeneca. These companies produce a variety of anxiolytic drugs, including benzodiazepines, SSRIs, and tricyclic antidepressants. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.